



October 24, 2017

Noramco and SPI Pharma sign letter of intent to develop formulation solution packages

Frankfurt, Germany - Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services, signed a letter of intent to develop and license formulation packages, specifically for implementation by their customers. The companies intend to deliver “ready-to-implement” patient-friendly drug formulations that provide convenience, compliance, and efficacy for such therapeutic indications as intense pain, opioid addiction, and central nervous system conditions (epilepsy, migraine, etc.).

Noramco has previously pledged to help its customers around the world accelerate pharmaceutical development with technical solutions packages. “Partnering with SPI Pharma enables Noramco to bring together API and functional excipient science to deliver innovative, patient-friendly solutions to formulators of finished dosage forms,” said Bill Grubb, VP Global Strategy and Innovation.

Grubb went on to say that going to generic and branded pharmaceutical customers with formulation packages allows Noramco and SPI Pharma to directly support speed-to-market, a reduction in trial-and-error, product differentiation, life-cycle management, and technical/regulatory support.

“Our customers will have the ability to work in a fee-for-service or royalty arrangement, and implement the technology at the facility they choose,” added Grubb.

Following a definitive agreement, which is expected in the next 30 days, testing of a select group of cannabinoid and addiction treatment APIs in unique dosage forms will commence to establish proof of concept (POC).

To learn more, visit SPI Pharma at booth #10.2B10, and Noramco at booth #111A21, during CPhI Frankfurt, 24-26 October 2017. For further information about each company, visit www.spipharma.com and www.noramco.com.

About Noramco

Noramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances and addiction treatment APIs for the pharmaceutical industry. The company offers products for use in attention deficit disorder, pain management, addiction management and abuse deterrence products. Established in 1979, Noramco maintains production and R&D facilities in Delaware and Georgia (USA); and Neuhausen, Switzerland; and accesses agricultural operations in Tasmania through an affiliate, Tasmanian Alkaloids.

About SPI Pharma

SPI Pharma, headquartered in Wilmington, Delaware, provides innovative solutions to global pharmaceutical and nutritional customers. Product lines include Antacid Actives, Excipients, Drug Delivery Systems, Taste-Masking, and Vaccine Adjuvants. SPI Pharma specializes in drug development services, having participated in over 60 commercially launched and marketed drugs globally. Leveraging the backing of its parent company, Associated British Foods, and its sites in the US, France and India, the company solves the most challenging formulation problems efficiently, cost-effectively, and with a focus on service.

– Ends –

SPI Pharma Contact;

Bob Duffy
Global Business Development Manager
rduffy@spipharma.com

Noramco Contact;

Anthony Ambrosini
Vice President, Business Development
aambrosi@noramco.com